[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-mediastinal-large-b-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":294,"states":313},"Primary Mediastinal Large B-Cell Lymphoma",47,38,[8,16,22,28,34,40,46,52,59,65,71,78,84,90,96,102,108,114,121,126,132,138,144,150,156,162,168,174,180,186,191,197,203,208,214,220,226,231,237,244,250,256,262,268,275,282,288],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04745949","PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy",[12],"Phase 2","RECRUITING","2026-08-26T02:19:27.519777Z","2026-04-29T02:57:57.080381Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06500273","Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",[12],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.207810Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05934448","Pembro Plus CAR T-cell Therapy in R\u002FR in PMBCL",[12],"2026-08-26T02:16:29.226604Z","2026-05-05T02:43:27.574296Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT07365306","Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:27.484467Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT06238648","Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",[12],"2026-08-26T02:16:26.411851Z","2026-05-05T02:43:27.434210Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT05633615","Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma",[12],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:27.059186Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT06784726","Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",[12],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.722685Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":57,"content_modified":58},"NCT06014502","Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors",[56],"Phase 1","2026-08-26T02:16:28.221034Z","2026-07-19T19:36:05.129130Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[56],"2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[12],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":76,"content_modified":77},"NCT07123454","A Phase I\u002FII Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[75],"Phase 1\u002FPhase 2","2026-08-26T02:19:29.119921Z","2026-07-05T05:32:16.737268Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[12],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[75],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05260957","CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory\u002FRelapsed Aggressive Non-Hodgkin's Lymphoma (NHL).",[12],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.501361Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06484920","A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:29.397408Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07283822","Amping up With PemJAK",[12],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.349629Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07098364","ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed\u002FRefractory Large B-Cell Lymphoma",[75],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.072273Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":119,"content_modified":120},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[118],"Phase 3","2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":69,"content_modified":125},"NCT05077527","Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma",[56],"2026-05-05T02:43:29.044473Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05544019","Study of SGR-1505 in Mature B-Cell Neoplasms",[56],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:28.973931Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[56],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06285825","A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia",[12],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.728703Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[75],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT05826535","Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma",[75],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.542914Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL",[12],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.289405Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[56],"2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT04186520","CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",[75],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:27.998949Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT06026319","CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",[56],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.943297Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[75],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":154,"content_modified":190},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[12],"2026-05-05T02:43:27.261789Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT05672251","Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.249867Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT06811272","Outpatient Epcoritamab as 2L in NTE R\u002FR DLBCL",[12],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:26.689921Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":32,"content_modified":207},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[12],"2026-05-05T02:43:26.687370Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT06536049","Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",[75],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:26.676281Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT06173518","A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",[56],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.644184Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT06144151","A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity",[],"2026-08-26T02:16:01.079019Z","2026-05-13T02:55:06.421955Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":76,"content_modified":230},"NCT06784167","Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment",[],"2026-05-13T02:55:06.577586Z",{"nct_id":232,"title":233,"phases":234,"status":13,"updated_at":235,"content_modified":236},"NCT05255354","Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy",[],"2026-08-26T02:15:04.877798Z","2026-05-13T02:55:06.298844Z",{"nct_id":238,"title":239,"phases":240,"status":241,"updated_at":242,"content_modified":243},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z",{"nct_id":245,"title":246,"phases":247,"status":241,"updated_at":248,"content_modified":249},"NCT07225439","Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed\u002FRefractory (r\u002Fr) B-cell Non-Hodgkin Lymphoma (NHL)",[56],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:29.483502Z",{"nct_id":251,"title":252,"phases":253,"status":241,"updated_at":254,"content_modified":255},"NCT07714421","Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",[56],"2026-08-26T02:18:31.164304Z","2026-07-24T01:27:14.913588Z",{"nct_id":257,"title":258,"phases":259,"status":241,"updated_at":260,"content_modified":261},"NCT07711483","GLORY: Glofit-GemOx With Liso-Cel For Lymphoma",[12],"2026-08-26T02:19:23.493898Z","2026-07-19T19:36:05.096345Z",{"nct_id":263,"title":264,"phases":265,"status":241,"updated_at":266,"content_modified":267},"NCT07638982","Axatilimab + CAR-T for High-Risk Lymphoma",[56],"2026-08-26T02:15:39.267524Z","2026-06-14T18:39:22.257504Z",{"nct_id":269,"title":270,"phases":271,"status":272,"updated_at":273,"content_modified":274},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[56],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z",{"nct_id":276,"title":277,"phases":278,"status":279,"updated_at":280,"content_modified":281},"NCT05412290","Mosunetuzumab Consolidation Therapy After autoSCT in r\u002Fr Aggressive B Cell Lymphoma",[56],"ACTIVE_NOT_RECRUITING","2026-08-03T03:30:23.638222Z","2026-05-05T02:43:28.878051Z",{"nct_id":283,"title":284,"phases":285,"status":279,"updated_at":286,"content_modified":287},"NCT06014762","P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies",[56],"2026-08-03T02:04:34.624671Z","2026-05-05T02:43:27.986911Z",{"nct_id":289,"title":290,"phases":291,"status":279,"updated_at":292,"content_modified":293},"NCT05821088","Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed\u002F Refractory Large B-Cell Lymphoma",[12],"2026-08-03T03:19:35.241322Z","2026-05-05T02:43:26.683044Z",[295,299,302,306,310],{"biomarker":296,"count":297,"slug":298},"CD19 Gene",9,"cd19-gene",{"biomarker":300,"count":297,"slug":301},"MS4A1 Gene","ms4a1-gene",{"biomarker":303,"count":304,"slug":305},"BCL2 Gene",4,"bcl2-gene",{"biomarker":307,"count":308,"slug":309},"BCL6 Gene",3,"bcl6-gene",{"biomarker":311,"count":308,"slug":312},"MYC Gene","myc-gene",[314,318,322,326,330,334,337,340,343,347,350,353,357,360,363,366,369,373,376,379,383,386,389,392],{"state":315,"count":316,"slug":317},"California",16,"california",{"state":319,"count":320,"slug":321},"Ohio",15,"ohio",{"state":323,"count":324,"slug":325},"New York",14,"new-york",{"state":327,"count":328,"slug":329},"Texas",13,"texas",{"state":331,"count":332,"slug":333},"Florida",12,"florida",{"state":335,"count":297,"slug":336},"North Carolina","north-carolina",{"state":338,"count":297,"slug":339},"Pennsylvania","pennsylvania",{"state":341,"count":297,"slug":342},"Tennessee","tennessee",{"state":344,"count":345,"slug":346},"Illinois",8,"illinois",{"state":348,"count":345,"slug":349},"Minnesota","minnesota",{"state":351,"count":345,"slug":352},"Washington","washington",{"state":354,"count":355,"slug":356},"Arizona",7,"arizona",{"state":358,"count":355,"slug":359},"Georgia","georgia",{"state":361,"count":355,"slug":362},"Massachusetts","massachusetts",{"state":364,"count":355,"slug":365},"Oregon","oregon",{"state":367,"count":355,"slug":368},"Utah","utah",{"state":370,"count":371,"slug":372},"Colorado",6,"colorado",{"state":374,"count":371,"slug":375},"Kentucky","kentucky",{"state":377,"count":371,"slug":378},"Wisconsin","wisconsin",{"state":380,"count":381,"slug":382},"Missouri",5,"missouri",{"state":384,"count":381,"slug":385},"New Jersey","new-jersey",{"state":387,"count":381,"slug":388},"Virginia","virginia",{"state":390,"count":304,"slug":391},"Indiana","indiana",{"state":393,"count":304,"slug":394},"Kansas","kansas"]